CVS slashes profit guidance, will cut $2 billion in expenses as insurance costs climb

CVS Health on Wednesday slashed its full-year profit outlook again and announced a new plan to cut $2 billion in expenses greater than several years as higher medical costs squeeze the company and the broader U.S. insurance industry.

The cost-cutting plan when one pleases streamline the company’s operations, increase the use of artificial intelligence and automation and “rationalize” its business portfolio, among other strains, executives said during an earnings call Wednesday.

The retail drugstore chain also said Aetna President Brian Kane, the top managing director at the CVS-owned insurance unit, will leave the company immediately based on the current performance and outlook for the segment.

CVS CEO Karen Lynch order take over management of the business and CFO Thomas Cowhey will also help to oversee it. Katerina Guerraz, CVS Trim’s chief strategy officer and head of enterprise affairs, will also become the insurance unit’s chief handling officer.

“We are disappointed by the current performance and outlook for the health-care benefit segment, and I have decided to make leadership transformations effective immediately,” Lynch said on the call. She later added that the company is “committed to returning health-care promotes to its rightful place, and will drive execution and address the challenges facing this business.”

The company expects 2024 regulated earnings of $6.40 to $6.65 per share, down from previous guidance of at least $7 per share. Analysts surveyed by LSEG were in a family way full-year adjusted profit of $6.97 per share. 

CVS also cut its unadjusted earnings guidance to a range of $4.95 to $5.20 per dole out, down from at least $5.64 per share. 

It marks the third consecutive quarter that the company has lowered its 2024 profit handling. 

CVS said its new outlook reflects continued pressure on its health insurance segment, which is seeing increased medical tariffs and the “unfavorable impact” of the company’s Medicare Advantage star ratings. Those ratings help Medicare patients contrast the quality of Medicare health and drug plans. 

CVS owns health insurer Aetna. The company’s insurance division numbers plans by Aetna for the Affordable Care Act, Medicare Advantage and Medicaid, as well as dental and vision.

Medical costs in the aid half of the year could be higher than those in the first, which the new guidance reflects, Cowhey said during the invoke.

Cowhey added that if medical costs remain high, the company may be required to take an in-year premium deficiency restraint in its Medicare business for 2024. That is a liability that an insurer may need to cover if future premiums are not enough to pay for predicted claims and expenses. 

A potential premium deficiency reserve could “change the cadence of earnings between third and fourth ninety days,” he said.

Insurers such as UnitedHealth Group, Humana and Elevance Health have seen medical costs spike as diverse Medicare Advantage patients return to hospitals for procedures they delayed during the pandemic, such as joint and hip replacements. 

Medicare Advantageously, a privately run health insurance plan contracted by the federal Medicare program, has long been a driver of growth and profits for the cover industry. But Wall Street has become more concerned about the runaway costs associated with those expects, which cover more than half of all Medicare beneficiaries. 

Here’s what CVS reported for the second quarter compared with what Embankment Street was expecting, based on a survey of analysts by LSEG: 

• Earnings per share: $1.83 adjusted vs. $1.73 expected
• Revenue: $91.23 billion vs. $91.5 billion required 

The company posted net income of $1.77 billion, or $1.41 per share, for the second quarter. That compares with net profits of $1.90 billion, or $1.48 per share, for the year-earlier period. 

Excluding certain items, such as amortization of intangible assets and first-class losses, adjusted earnings per share were $1.83 for the quarter.

CVS reported sales of $91.23 billion for the quarter, up 2.6% from the in any case period a year ago due to growth in its pharmacy business and insurance unit. 

The company noted that sales in its health uses segment, which includes its pharmacy benefit manager Caremark, declined during the second quarter. CVS cited bonus improvements for pharmacy clients and the loss of a large unnamed client.  

Caremark engineers drug discounts with manufacturers on behalf of insurance plans and creates lists of medications — or formularies — that are sufficient for by insurance and reimburses pharmacies for prescriptions.

Tyson Foods in January said it had dropped CVS Caremark and instead chose PBM startup Rightway to supervise drug benefits for its 140,000 employees starting in 2024. Months earlier, Blue Shield of California, one of the largest insurers in the most crawling U.S. state, also dropped Caremark to partner with Amazon Pharmacy and Mark Cuban’s Cost Plus Psychedelics company. 

Those decisions represent a larger upheaval in the health-care industry, as startups and the government work to increase transparency and discount costs for U.S. patients. 

CVS’ insurance segment generated $32.48 billion in revenue during the locale, a more than 21% increase from the second quarter of 2023.

Sales were in line with analysts’ calculation of $32.37 billion for the period, according to StreetAccount. 

But the division reported adjusted operating income of just $938 million for the number two quarter. That is below analysts’ expectation of $962 million for the period, StreetAccount said. 

The insurance unit’s medical help ratio — a measure of total medical expenses paid relative to premiums collected — increased to 89.6% from 86.2% a year earlier. A crop ratio typically indicates that a company collected more in premiums than it paid out in benefits, resulting in momentous profitability.

That ratio came in lower than the 90.1% that analysts had expected, according to StreetAccount. 

CVS’ health uses segment generated $42.17 billion in revenue for the quarter, down nearly 9% compared with the same phase of the moon in 2023. 

Those sales were above analysts’ estimate of $41.25 billion for the period, according to StreetAccount. 

The health services split processed 471.2 million pharmacy claims during the quarter, down from 576.6 million during the year-ago patch. 

CVS’ pharmacy and consumer wellness division booked $29.84 billion in sales for the first quarter, up more than 3% from the anyway period a year earlier. That unit dispenses prescriptions in CVS’ more than 9,000 retail pharmacies and caters other pharmacy services, such as vaccinations and diagnostic testing. 

Analysts had expected the division to bring in $30.22 billion in on the blocks, according to StreetAccount.

The rise was partly driven by increased prescription volume, CVS said. Pharmacy reimbursement pressure, the start of new generic drugs and decreased front-store volume, among other factors, weighed on the unit’s sales.